An updated evolutionary classification of CRISPR–Cas systems including rare variants
Kira S. Makarova (National Institutes of Health)
Sergey A. Shmakov (National Institutes of Health)
Yuri I. Wolf (National Institutes of Health)
Pascal Mutz (National Institutes of Health)
Han Altae-Tran (University of Washington)
Chase L. Beisel (Julius-Maximilians-Universität Würzburg, Helmholtz Centre for Infection Research (HZI))
Stan J.J. Brouns (TU Delft - BN/Stan Brouns Lab, Kavli institute of nanoscience Delft)
David Cheng (Student TU Delft)
Shiraz A. Shah (University of Copenhagen)
undefined More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The known diversity of CRISPR–Cas systems continues to expand. To encompass new discoveries, here we present an updated evolutionary classification of CRISPR–Cas systems. The updated CRISPR–Cas classification includes 2 classes, 7 types and 46 subtypes, compared with the 6 types and 33 subtypes in our previous survey 5 years ago. In addition, a classification of the cyclic oligoadenylate-dependent signalling pathway in type III systems is presented. We also discuss recently characterized alternative CRISPR–Cas functionalities, notably, type IV variants that cleave the target DNA and type V variants that inhibit the target replication without cleavage. Analysis of the abundance of CRISPR–Cas variants in genomes and metagenomes shows that the previously defined systems are relatively common, whereas the more recently characterized variants are comparatively rare. These low abundance variants comprise the long tail of the CRISPR–Cas distribution in prokaryotes and their viruses, and remain to be characterized experimentally.
help_outline